INCYNASDAQHealthcare

INCYTE CORP

Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.

Latest price

$119.65

+1.39%

Alpha Vantage · 11/6/2026

Industry: BiotechnologyCategory: Domestic Common StockCurrency: USDNews: 1 recent

Analyze INCY free

One-year price history

Adjusted daily closes · 252 observations · as of Nov 6, 2026

Historical data, not a forecast

1 month

+6.1%

3 months

-1.6%

6 months

+21.4%

1 year

+13.7%

Year to date

+21.1%

52-week range

$90.30 – $129.93

Fundamental snapshot

Latest reported period: Sep 30, 2026

Sharadar reported data

Market cap

$24.39B

P/E

60.5

P/B

4.3

P/S

4.1

Revenue

$6.01B

Net income

$403.41M

Diluted EPS

1.88

Gross margin

92.70%

Net margin

6.70%

Return on equity

7.10%

Total debt

$31.76M

Cash

$3.28B

Free cash flow

$684.87M

Latest eight reported quarters

Reported quarterly values, newest first

Period	Revenue	Net income	Gross margin	Net margin	Free cash flow
Sep 30, 2026	$1.56B	-$784.8M	93.00%	-50.40%	-$690.95M
Jun 30, 2026	$1.67B	$585.61M	93.70%	35.00%	$495.25M
Mar 31, 2026	$1.27B	$303.33M	91.80%	23.80%	$359.15M
Dec 31, 2025	$1.51B	$299.28M	92.00%	19.90%	$521.42M
Sep 30, 2025	$1.37B	$424.17M	92.80%	31.10%	$544.64M
Jun 30, 2025	$1.22B	$405M	93.50%	33.30%	$25.67M
Mar 31, 2025	$1.05B	$158.2M	93.00%	15.00%	$262.9M
Dec 31, 2024	$1.18B	$201.21M	92.50%	17.10%	$363.83M

Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.

Recent INCY news

All market news

BioSpace·Nov 5, 202660 signal

Xencor Reports Third Quarter 2026 Financial Results

Xencor, Inc. reported its financial results for the third quarter ended September 30, 2026, highlighting progress across its clinical-stage pipeline for cancer and autoimmune diseases. Key updates include compelling clinical data for XmAb819 in advanced clear cell renal cell carcinoma, upcoming presentations for plamotamab in rheumatoid arthritis, and on-track development for TL1A-targeting programs XmAb942 and XmAb412. The company also detailed significant milestones achieved with partners Amgen, Astellas, and Zenas BioPharma, and reported a net income of $39.4 million for the quarter.

Original source